Diametric Capital LP Boosts Stock Holdings in Liquidia Co. (NASDAQ:LQDA)

Diametric Capital LP lifted its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 6.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,028 shares of the company’s stock after buying an additional 7,696 shares during the quarter. Liquidia comprises 1.1% of Diametric Capital LP’s investment portfolio, making the stock its 16th biggest position. Diametric Capital LP owned about 0.16% of Liquidia worth $1,553,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets raised its holdings in Liquidia by 735.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after acquiring an additional 123,402 shares during the period. Barclays PLC raised its stake in shares of Liquidia by 265.0% during the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after purchasing an additional 72,591 shares during the period. Whitefort Capital Management LP lifted its holdings in Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after purchasing an additional 927,546 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after purchasing an additional 210,753 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $14.75 on Tuesday. The firm has a fifty day moving average of $15.14 and a 200 day moving average of $12.47. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.81. The firm has a market capitalization of $1.26 billion, a PE ratio of -9.05 and a beta of 0.07.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The firm had revenue of $2.92 million during the quarter, compared to analysts’ expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, sell-side analysts forecast that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $73,613.22. Following the completion of the sale, the insider now owns 270,388 shares of the company’s stock, valued at approximately $3,185,170.64. This represents a 2.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Kaseta sold 23,370 shares of the business’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares of the company’s stock, valued at $4,732,673.90. This represents a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock worth $843,326 over the last ninety days. Insiders own 30.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LQDA shares. Scotiabank reissued an “outperform” rating on shares of Liquidia in a report on Thursday, March 20th. Wells Fargo & Company assumed coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research report on Thursday, March 20th. Finally, Needham & Company LLC increased their price objective on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Liquidia has a consensus rating of “Buy” and an average target price of $26.63.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).